- •In this subanalysis of the DAPA-VO2 randomized clinical trial, dapagliflozin led to a significant short-term increase in hemoglobin.
- •Short-term hemoglobin changes were associated with the magnitude of between-treatment differences (dapagliflozin vs. placebo) in maximal functional capacity, quality of life, and natriuretic peptides.
- •The magnitude of hemoglobin increase emerges as a simple and widely available parameter for monitoring SGLT2i response.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Cardiac Failure
- Effects of SGLT2 inhibitors on haematocrit and haemoglobin levels and the associated cardiorenal benefits in T2DM patients: A meta-analysis.J Cellular Molecular Medi. 2022; 26: 540-547https://doi.org/10.1111/jcmm.17115
- DAPA-VO2 Investigators. Short-term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA-VO2): a randomized clinical trial.Eur J Heart Fail. 2022; (Epub ahead of print)https://doi.org/10.1002/ejhf.2560
- Rates of Reversal of Volume Overload in Hospitalized Acute Heart Failure: Association With Long-term Kidney Function.Am J Kidney Dis. 2022; 80: 65-78https://doi.org/10.1053/j.ajkd.2021.09.026
- The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure.J Card Fail. 2021; 27: 1447-1455https://doi.org/10.1016/j.cardfail.2021.07.003
- Dapagliflozin suppresses hepcidin and increases erythropoiesis.J Clin Endocrinol Metab. 2020; 105 (10.1159/000507272): dgaa057https://doi.org/10.1210/clinem/dgaa057
- Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.Circulation. 2020; 141: 704-707https://doi.org/10.1161/CIRCULATIONAHA.119.044235
- DAPA-HF Investigators and Committees. Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF.Circulation. 2022; (Epub ahead of print)https://doi.org/10.1161/CIRCULATIONAHA.122.060511
- Potential role of empagliflozin in myocardial iron repletion following ferric carboxymaltose for heart failure.Rev Esp Cardiol (Engl Ed). 2022; (Epub ahead of print)https://doi.org/10.1016/j.rec.2022.06.003
Publication stageIn Press Journal Pre-Proof
Acknowledgements: Authors acknowledge all the DAPA-VO2 Investigators: Jose Civera, Adriana Conesa, Rim Zakarne, Clara Jiménez Rubio, Alejandro I. Pérez Cabeza, Arancha Díaz Expósito, José David Martínez Carmona, Manuel Luna Morales, Francisco J. Zafra Sánchez, Ángel Montiel Trujillo, and Herminio Morillas Climent.
Authors’ Contributions: Miguel Lorenzo, Julio Núñez, Patricia Palau, Martina Amiguet, and Gema Miñana postulated the hypothesis, wrote the proposal, enrolled patients, and drafted the manuscript. Patricia Palau, Martina Amiguet, Julia Seller, Sandra Villar, Jose Manuel Garcia Pinilla, Jose Luis Górriz, Alfonso Valle, Rafael de la Espriella, and Eloy Domínguez were in charge of the main study protocol, conducted the cardiopulmonary exercise test, echocardiography, follow-up clinical visits, and participated in manuscript drafting. Eduardo Núñez participated in the design, statistical analysis of the results, and manuscript drafting. Vicent Bodí, Juan Sanchis, and Antoni Bayés-Genis participated in the clinical design, data analysis and critically reviewed the manuscript. All authors approved the final article
Funding: This work was supported in part by an unrestricted grant from Astra Zeneca, Unidad de Investigación Clínica y Ensayos Clínicos INCLIVA Health Research Institute, Spanish Clinical Research Network (SCReN; PT17/0017/0003 y PT20/00100), and CIBER Cardiovascular [grant numbers 16/11/00420, 16/11/00403, and 16/11/00486].
Conflict of interest: PP has received fees for participating in educational activities from Servier. M.A. reports personal fees from Astra Zeneca, Novartis, Boehringer-Ingelheim, Eli Lilly, and Pfizer. J.Seller. reports speaker fees from Astra Zeneca and Boehringer Ingelheim. JMGP reports personal fees from Astra Zeneca and Esteve. AV reports speaker fees from Astra Zeneca. R.E. reports personal fees from Astra Zeneca, Novartis, Boehringer-Ingelheim, and NovoNordisk. J.Sanchis. has received speaker fees from Abbott Vascular and Prosmédica. JLG has received fees for participating in advisory boards and educational activities from Astra Zeneca, Boehringer-Ingelheim, NovoNordisk, Bayer, and Novartis. A.B-G. has lectured and/or participated in advisory boards for Abbott, Astra Zeneca, Boehringer-Ingelheim, Novartis, Roche Diagnostics, and Vifor. J.N. reports personal fees from Astra Zeneca, Novartis, Boehringer-Ingelheim, Eli Lilly, Rovi, NovoNordisk, and Vifor Pharma.